# Arcus Biosciences Inc. (RCUS)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $2.38B  
**Price:** $22.12 (-6.43%)

> Arcus Biosciences Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. Focusing primarily on immuno-oncology, the company aims to harness the body's own immune system to target and eliminate cancer cells. Arcus Biosciences' pipeline includes a variety of monoclonal antibodies, small molecules, and combination therapies that address different aspects of cancer's complex biology. One of its core strategies is to develop next-generation treatments that can potentially improve upon existing therapies, enhancing efficacy while minimizing side effects. Operating in an industry marked by rapid scientific advancements, Arcus Biosciences plays a critical role in the ongoing pursuit of more effective cancer treatments. Its efforts contribute to the diversification of therapeutic options available to clinicians, offering hope to patients managing the challenges of cancer. Through strategic partnerships and robust research initiatives, Arcus Biosciences continues to expand its impact within the highly competitive biopharmaceutical sector, underscoring the importance of innovation in the battle against cancer.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $33M | — | -$386M | -$353M | $-3.29 |
| 2024 | $51M | — | -$330M | -$283M | $-3.14 |
| 2023 | $37M | — | -$340M | -$307M | $-4.15 |
| 2022 | $38M | — | -$280M | -$267M | $-3.71 |
| 2021 | $383M | — | $54M | $53M | $0.71 |
| 2020 | $78M | — | -$124M | -$123M | $-2.24 |
| 2019 | $15M | — | -$89M | -$85M | $-1.93 |
| 2018 | $8M | — | -$55M | -$50M | — |
| 2017 | $1M | — | -$53M | -$53M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.14B | $508M | $631M | $222M | $99M |
| 2024 | $1.15B | $665M | $485M | $150M | $48M |
| 2023 | $1.09B | $633M | $462M | $127M | — |
| 2022 | $1.34B | $688M | $657M | $206M | — |
| 2021 | $1.59B | $750M | $842M | $148M | — |
| 2020 | $772M | $270M | $502M | $173M | — |
| 2019 | $203M | $39M | $164M | $58M | — |
| 2018 | $275M | $40M | $235M | $71M | — |
| 2017 | $190M | $37M | -$72M | $98M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$482M | $2M | -$484M |
| 2024 | -$170M | $6M | -$176M |
| 2023 | -$306M | $24M | -$330M |
| 2022 | $438M | $6M | $432M |
| 2021 | -$256M | $26M | -$282M |
| 2020 | $111M | $3M | $108M |
| 2019 | -$73M | $2M | -$75M |
| 2018 | -$43M | $4M | -$47M |
| 2017 | -$25M | $6M | -$31M |
| 2016 | -$13M | $4M | -$17M |

Source: [CompaniesByCap](https://companiesbycap.com/company/RCUS)